Donate Help Contact The AHA Sign In Home
American Heart Association
Hypertension
Search: search_blue_button Advanced Search
Hypertension. 1999;33:671-675

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Grassi, G.
Right arrow Articles by Mancia, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Grassi, G.
Right arrow Articles by Mancia, G.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*AMLODIPINE BESYLATE
Medline Plus Health Information
*Heart Failure
Related Collections
Right arrow Congestive
Right arrow Cardiovascular Pharmacology
Right arrow Other diagnostic testing

(Hypertension. 1999;33:671-675.)
© 1999 American Heart Association, Inc.


Scientific Contributions

Effects of Amlodipine on Sympathetic Nerve Traffic and Baroreflex Control of Circulation in Heart Failure

Guido Grassi; Domenico Spaziani; Gino Seravalle; Giovanni Bertinieri; Raffaella Dell'Oro; Cesare Cuspidi; Giuseppe Mancia

From Cattedra di Medicina Interna, Università di Milano, Ospedale S.Gerardo, Monza (G.G., R.D., G.M.); the Centro di Fisiologia Clinica e Ipertensione IRCCS, Ospedale Maggiore, Milano (G.G., G.B., C.C., G.M.); the Divisione di Cardiologia, Ospedale di Legnano, Milano (D.S.); and IRCCS Centro Auxologico Italiano, Milano, Italy (G.S., G.M.)

Correspondence to Prof Giuseppe Mancia, Cattedra di Medicina Interna, Università di Milano, Ospedale S.Gerardo—Via Donizetti 106, 20052 Monza, Italy.

Abstract—Short-acting calcium antagonists exert a sympathoexcitation that in heart failure further enhances an already elevated sympathetic activity. Whether this is also the case for long-acting formulations is not yet established, despite the prognostic importance of sympathetic activation in heart failure. It is also undetermined whether in this condition long-acting calcium antagonists favorably affect a mechanism potentially responsible for the sympathetic activation, ie, the baroreflex impairment. In 28 heart failure patients (NYHA functional class II) under conventional treatment we measured plasma norepinephrine and efferent postganglionic muscle sympathetic nerve activity (microneurography) at rest and during arterial baroreceptor stimulation and deactivation induced by stepwise intravenous infusions of phenylephrine and nitroprusside, respectively. Measurements were performed at baseline and after 8 weeks of daily oral amlodipine administration (10 mg/d, 14 patients) or before and after an 8-week period without calcium antagonist administration (14 patients). Amlodipine caused a small and insignificant blood pressure reduction. Heart rate, left ventricular ejection fraction, and plasma renin and aldosterone concentrations were not affected. This was the case also for plasma norepinephrine (from 2.43±0.41 to 2.50±0.34 nmol/L, mean±SEM), muscle sympathetic nerve activity (from 54.4±5.9 to 51.0±4.3 bursts/min), and arterial baroreflex responses. No change in the above-mentioned variables was seen in the control group. Thus, in mild heart failure amlodipine treatment does not adversely affect sympathetic activity and baroreflex control of the heart and sympathetic tone. This implies that in this condition long-acting calcium antagonists can be administered without untoward neurohumoral effects anytime conventional treatment needs to be complemented by drugs causing additional vasodilatation.


Key Words: nervous system, sympathetic • nervous system, autonomic • baroreceptors • calcium antagonists • heart failure




This article has been cited by other articles:


Home page
HypertensionHome page
G. Grassi, G. Seravalle, F. Quarti-Trevano, F. Scopelliti, R. Dell'Oro, G. Bolla, and G. Mancia
Excessive Sympathetic Activation in Heart Failure With Obesity and Metabolic Syndrome: Characteristics and Mechanisms
Hypertension, March 1, 2007; 49(3): 535 - 541.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
Y. Zhong, K.-M. Jan, K. H. Ju, and K. H. Chon
Quantifying cardiac sympathetic and parasympathetic nervous activities using principal dynamic modes analysis of heart rate variability
Am J Physiol Heart Circ Physiol, September 1, 2006; 291(3): H1475 - H1483.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
G. Grassi, G. Seravalle, C. Turri, G. Bolla, and G. Mancia
Short-Versus Long-Term Effects of Different Dihydropyridines on Sympathetic and Baroreflex Function in Hypertension
Hypertension, March 1, 2003; 41(3): 558 - 562.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
C. Binggeli, R. Corti, I. Sudano, T. F. Luscher, and G. Noll
Effects of Chronic Calcium Channel Blockade on Sympathetic Nerve Activity in Hypertension
Hypertension, April 1, 2002; 39(4): 892 - 896.
[Abstract] [Full Text] [PDF]